Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Selecting Therapy for Relapsed/Refractory MCL

January 18th 2019

Optimizing Therapeutic Approaches to MCL

January 18th 2019

Mantle Cell Lymphoma: An Overview of Therapy

January 18th 2019

Distinguishing MCL From Other Lymphomas

January 18th 2019

Mantle Cell Lymphoma: Impact of Genetic Variants

January 18th 2019

Understanding the Heterogeneity of Mantle Cell Lymphoma

January 18th 2019

Dr. Wong on an Investigational Antibody-Drug Conjugate in Multiple Myeloma

January 18th 2019

Sandy Wong, MD, assistant professor, University of California, San Francisco (UCSF) School of Medicine, discusses an investigational antibody-drug conjugate (ADC) in multiple myeloma.

Dr. Martin on Selinexor in Penta-Refractory Patients With Myeloma

January 15th 2019

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco (UCSF); co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the potential of selinexor in penta-refractory patients with multiple myeloma.

Targeting BCL-2 in Hematologic Malignancies

January 11th 2019

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Costimulatory Agonists Start to Bear Fruit in Oncology

January 11th 2019

Aaron R. Hansen, BSc, MBBS, discusses progress with costimulatory immune checkpoints in oncology.

BCL-2: Mechanisms and Prevalence

January 10th 2019

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.

Insight on Advances in the Treatment of AML

January 10th 2019

Immunotherapy for AML

January 10th 2019

IDH Inhibitors for AML

January 10th 2019

Resistance Mechanisms in AML and Treatment Decisions

January 10th 2019

Quizartinib for FLT3-Mutated AML

January 10th 2019

Gilteritinib for FLT3-Mutant AML

January 10th 2019

Midostaurin for FLT3-Mutant AML

January 10th 2019

Significance of FLT3 Mutations in AML

January 10th 2019

Maintenance Therapy for AML

January 10th 2019